Publication | Closed Access

A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy

Bone DiseaseSurgical OncologyBreast OncologyPhase Ii TrialBreast Cancer PatientsMedicineBreast CancerOsteoporosisStandard BisphosphonateCancer TreatmentOncologyRadiation OncologyOrthopaedic Surgery